Changes in the defined daily dose; CYP2D6/CYP3A metabolism as an indicator for dose-setting problems

European Journal of Clinical Pharmacology

Volumn 61, Issue 3, 2005, Pages 243-246

  Stolk, P ^a   Heerdink, E R ^a   Leufkens, H G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cytochrome P 450; Dosing changes; Label changes; Pharmacoepidemiology; Pharmacogenetics; Regulatory affairs

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A;

ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; DRUG DOSE REGIMEN; DRUG LABELING; DRUG METABOLISM; INFORMATION RETRIEVAL; INTERNET; PHARMACOEPIDEMIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; WORLD HEALTH ORGANIZATION;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 20044395315     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0906-9     Document Type: Article

References (15)

1. Jefferys DB, Leakey D, Lewis JA, Payne S, Rawlins MD (1998) New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol 45:151-156
2. Stricker BH, Psaty BM (2004) Detection, verification, and quantification of adverse drug reactions. BMJ 329:44-47
3. Cross J, Lee H, Westelinck A, Nelson J, Grudzinskas C, Peck C (2002) Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol Drug Saf 11:439-446
4. Heerdink ER, Urquhart J, Leufkens HG (2002) Changes in prescribed drug doses after market introduction. Pharmacoepidemiol Drug Saf 11:447-453
5. Tucker GT, Houston JB, Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. Br J Clin Pharmacol 52:107-117
6. Richter A, Anton SE, Koch P, Dennett SL (2003) The impact of reducing dose frequency on health outcomes. Clin Ther 25:2307-2335
7. Weinshilboum R (2003) Inheritance and drug response. N Engl J Med 348:529-537
8. Temple R (1989) Dose-response and registration of new drugs. In: Lasagna L, Erill S, Naranjo CA (eds) Dose-response relationships in clinical pharmacology. Elsevier, Amsterdam, pp 145-167
9. Ingelman-Sundberg M (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25:193-200
10. WHO Collaborating Centre for Drug Statistics Methodology (2004) About the ATC/DDD system. http://www.whocc.no/atcddd/atcsystem.html. Accessed 17 July 2004
11. Indiana University Department of Medicine, Division of Clinical Pharmacology (2004) Cytochrome P450 drug interaction table. http://medicine. iupui.edu/flockhart/table.htm. Accessed 6 July 2004
12. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294
13. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I et al (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442-473
14. Schelleman H, Stricker BH, De Boer A, Kroon AA, Verschuren MW, Van Duijn CM et al (2004) Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs 64:1801-1816
15. Ito K, Brown HS, Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486